01.08.2012 - Merck Serono has spun off the first company as part of its Entrepreneur Partnership Program. The project was launched in April 2012 when mother company Merck KGaA in Darmstadt had decided to end its activities in Geneva.
Newco Prexton Therapeutics will be formed around Merck Serono's R&D portfolio in the field of Parkinson's disease and will focus on programmes that target the metabotropic glutamate receptors mGluR3 and mGluR4. Prexton will be hosted in the offices and laboratory of Eclosion, a biotech start-up incubator supported by the Geneva authorities and Merck Serono which will invest €2.1m as seed funding. Helping spin-off companies such as Prexton was one of Merck Serono’s proposals to employee groups unsatisfied by social plan and severance options. In total, the pharma has reserved €30m to back start-ups by employees at its operations in Geneva. Prexton will be run by a team of Merck Serono scientists, with a member of Merck Serono Ventures on the board of directors.
12.02.2016 The promise of the microbiome as the basis of new treatments has caught the attention of many. Now, UK biotherapeutics maker 4D pharma plc has padded its microbiome pipeline with the acquisition of Irish Tucana Health.
05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.
04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.
01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.
27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.
25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.
21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.